ClearPoint Neuro (CLPT) director receives 1,270-share stock grant as fees

Rhea-AI Filing Summary

FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.

ClearPoint Neuro director R. John Fletcher received 1,270 shares of common stock as a grant. The shares were issued at $9.10 per share under the company’s incentive compensation plan as payment of fees owed under the Non-Employee Director Compensation Plan.

Following this compensation-related issuance, Fletcher directly holds 117,932 shares of ClearPoint Neuro common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FLETCHER R JOHN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,270	$9.10	$12K

Holdings After Transaction: Common Stock — 117,932 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 1,270 shares Grant price: $9.10 per share Shares owned after grant: 117,932 shares

3 metrics

Shares granted 1,270 shares Common stock grant on April 1, 2026

Grant price $9.10 per share Closing price on March 31, 2026

Shares owned after grant 117,932 shares Direct holdings following Form 4 transaction

Key Terms

Sixth Amended and Restated 2013 Incentive Compensation Plan, Non-Employee Director Compensation Plan, closing price

3 terms

Sixth Amended and Restated 2013 Incentive Compensation Plan financial

"These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan"

Non-Employee Director Compensation Plan financial

"in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan"

closing price financial

"The shares were issued at the closing price of the issuer's common stock at March 31, 2026"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FLETCHER R JOHN

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		1,270	A	$9.1(1)	117,932	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2026.

	/s/ Danilo D'Alessandro, by Power of Attorney for R. John Fletcher	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CLPT director R. John Fletcher report?

R. John Fletcher reported receiving 1,270 shares of ClearPoint Neuro common stock. The shares were granted as part of his director compensation, not bought on the open market, and were issued under the company’s incentive compensation and non-employee director compensation plans.

At what price were the CLPT shares granted to director R. John Fletcher?

The 1,270 ClearPoint Neuro (CLPT) shares granted to R. John Fletcher were issued at $9.10 per share. This price reflects the closing price of the company’s common stock on March 31, 2026, as specified in the compensation-related footnote.

How many CLPT shares does R. John Fletcher own after this Form 4 transaction?

After the reported grant, R. John Fletcher directly owns 117,932 ClearPoint Neuro (CLPT) shares. This updated holding reflects the 1,270-share issuance made as payment of fees under the company’s non-employee director compensation arrangements.

Was the CLPT Form 4 transaction a market purchase or a compensation grant?

The CLPT Form 4 transaction was a compensation grant, not a market purchase. The 1,270 shares were issued under ClearPoint Neuro’s Sixth Amended and Restated 2013 Incentive Compensation Plan to pay fees owed under the Non-Employee Director Compensation Plan.

Which plans governed the CLPT share grant to director R. John Fletcher?

The share grant was issued under ClearPoint Neuro’s Sixth Amended and Restated 2013 Incentive Compensation Plan. It satisfied fees owed to R. John Fletcher under the company’s Non-Employee Director Compensation Plan, as amended and restated, according to the filing footnote.